See Supplemental Patient Information
- Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria have occurred in some patients following systemic absorption; avoid application of more potent steroids over large surface areas during prolonged use and addition of occlusive dressings, as these may augment systemic absorption. Periodically evaluate patients for evidence of HPA axis suppression by performing the urinary free cortisol and ACTH stimulation tests. Also, assess for impairment of internal homeostasis
- On occurrence of HPA axis suppression or elevation of the body temperature, make attempt to withdraw the drug, to reduce the frequency of application, or substitute with a less potent steroid
- Provide supplemental systemic corticosteroids on occurrence of withdrawal symptoms
- Pediatric patients are more prone to systemic toxicity
- Discontinue therapy on occurrence of irritation or hypersensitivity and provide appropriate therapy
- Perform appropriate microbiological studies (e.g. KOH smears and/or cultures) on lack of therapeutic response. Confirm the diagnosis and rule out other pathogens, before instituting another course of therapy
Caution: Use cautiously in:
Supplemental Patient Information
- Advise patients to avoid treated skin being bandaged, covered or wrapped as to be occluded
- Advise patients to report on occurrence of signs of local adverse reactions
- Advise patients to wear loose fitting clothing on applying medication in the inguinal area
- Advise patients to avoid contact with the eyes
- Educate patients for preventive measures to avoid reinfection
- Advise patients to avoid using this medication in disorders other than for which it was prescribed
- Advise parents of pediatric patients to avoid tight-fitting diapers or plastic pants if being treated in the diaper area
Pregnancy Category:C
Breastfeeding: Safety unknown; Literature unavailable on excretion of nystatin in milk. Acceptable for use in nursing mothers including topical application to the nipples as virtually unabsorbed on oral use. Topical use of triamcinolone has not been studied during breastfeeding. Unlikely that short-term application of topical corticosteroids would pose a risk to the breastfed infant. Use least potent drug on the smallest area of skin. Ensure that the infant's skin does not come into direct contact with the areas of treated skin. Only water-miscible cream products should be applied to the breast as ointments may expose the infant to high levels of mineral paraffins via licking. Remove any excess cream from the nipples before nursing. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 3 December 2010). Manufacturer advises caution while using in nursing women
US Trade Name(s)
US Availability
nystatin/triamcinolone (generic)
- CRE: 100,000 units per g/0.1%
- OINT: 100,000 units per g/0.1%
Mykacet (nystatin/triamcinolone)
- CRE: 100,000 units per g/0.1%
- OINT: 100,000 units per g/0.1%
Canadian Trade Name(s)
Canadian Availability
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability
Pricing data from www.DrugStore.com in U.S.A.
- Nystatin-Triamcinolone 100000-0.1 UNIT/GM-% CREA [Tube] (TARO)
60 gm-% = $49.99
120 gm-% = $90.97 - Nystatin-Triamcinolone 100000-0.1 UNIT/GM-% CREA [Tube] (TARO)
15 gm-% = $29.99
45 gm-% = $67.97 - Nystatin-Triamcinolone 100000-0.1 UNIT/GM-% CREA [Tube] (TARO)
30 gm-% = $37.99
60 gm-% = $64.97 - Nystatin-Triamcinolone 100000-0.1 UNIT/GM-% OINT [Tube] (TARO)
60 gm-% = $59.99
180 gm-% = $165.97 - Nystatin-Triamcinolone 100000-0.1 UNIT/GM-% OINT [Tube] (TARO)
30 gm-% = $45.99
60 gm-% = $82.97 - Nystatin-Triamcinolone 100000-0.1 UNIT/GM-% OINT [Tube] (TARO)
15 gm-% = $34.99
30 gm-% = $59.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.